Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.

Sumodhee S, Bondiau PY, Poudenx M, Cohen C, Naghavi AO, Padovani B, Maneval D, Gal J, Leysalle A, Ghalloussi H, Otto J, Doyen J.

BMC Cancer. 2019 Apr 3;19(1):305. doi: 10.1186/s12885-019-5542-3.

2.

pGPUMCD: an efficient GPU-based Monte Carlo code for accurate proton dose calculations.

Maneval D, Ozell B, Després P.

Phys Med Biol. 2019 Apr 12;64(8):085018. doi: 10.1088/1361-6560/ab0db5.

PMID:
30844777
3.

ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

Locke KW, Maneval DC, LaBarre MJ.

Drug Deliv. 2019 Dec;26(1):98-106. doi: 10.1080/10717544.2018.1551442. Review. Erratum in: Drug Deliv. 2019 Mar 25;:1.

4.

Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression.

Li X, Shepard HM, Cowell JA, Zhao C, Osgood RJ, Rosengren S, Blouw B, Garrovillo SA, Pagel MD, Whatcott CJ, Han H, Von Hoff DD, Taverna DM, LaBarre MJ, Maneval DC, Thompson CB.

Clin Cancer Res. 2018 Oct 1;24(19):4798-4807. doi: 10.1158/1078-0432.CCR-17-3284. Epub 2018 Jul 3.

5.

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.

Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK.

Br J Cancer. 2018 Jan;118(2):e3. doi: 10.1038/bjc.2017.438.

6.

Efficiency improvement in proton dose calculations with an equivalent restricted stopping power formalism.

Maneval D, Bouchard H, Ozell B, Després P.

Phys Med Biol. 2017 Dec 19;63(1):015019. doi: 10.1088/1361-6560/aa9166.

PMID:
28980975
7.

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.

Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK.

Br J Cancer. 2018 Jan;118(2):153-161. doi: 10.1038/bjc.2017.327. Epub 2017 Sep 26. Erratum in: Br J Cancer. 2018 Jan;118(2):e3.

8.

PH20 is not expressed in murine CNS and oligodendrocyte precursor cells.

Marella M, Ouyang J, Zombeck J, Zhao C, Huang L, Connor RJ, Phan KB, Jorge MC, Printz MA, Paladini RD, Gelb AB, Huang Z, Frost GI, Sugarman BJ, Steinman L, Wei G, Shepard HM, Maneval DC, Lapinskas PJ.

Ann Clin Transl Neurol. 2017 Feb 23;4(3):191-211. doi: 10.1002/acn3.393. eCollection 2017 Mar.

9.

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB.

AAPS J. 2015 Nov;17(6):1523-4. doi: 10.1208/s12248-015-9822-9. No abstract available.

10.

Folate-mediated one-carbon metabolism genes and interactions with nutritional factors on colorectal cancer risk: Women's Health Initiative Observational Study.

Cheng TY, Makar KW, Neuhouser ML, Miller JW, Song X, Brown EC, Beresford SA, Zheng Y, Poole EM, Galbraith RL, Duggan DJ, Habermann N, Bailey LB, Maneval DR, Caudill MA, Toriola AT, Green R, Ulrich CM.

Cancer. 2015 Oct 15;121(20):3684-91. doi: 10.1002/cncr.29465. Epub 2015 Jun 24.

11.

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB.

AAPS J. 2015 Sep;17(5):1144-56. doi: 10.1208/s12248-015-9782-0. Epub 2015 May 13. Erratum in: AAPS J. 2015 Nov;17(6):1523-4.

12.

Biomarkers of one-carbon metabolism are associated with biomarkers of inflammation in women.

Abbenhardt C, Miller JW, Song X, Brown EC, Cheng TY, Wener MH, Zheng Y, Toriola AT, Neuhouser ML, Beresford SA, Makar KW, Bailey LB, Maneval DR, Green R, Manson JE, Van Horn L, Ulrich CM.

J Nutr. 2014 May;144(5):714-21. doi: 10.3945/jn.113.183970. Epub 2014 Mar 19.

13.

Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.

Dychter SS, Harrigan R, Bahn JD, Printz MA, Sugarman BJ, DeNoia E, Haughey DB, Fellows D, Maneval DC.

Clin Ther. 2014 Feb 1;36(2):211-24. doi: 10.1016/j.clinthera.2013.12.013. Epub 2014 Jan 31.

PMID:
24486335
14.

Impact of folic acid fortification on global DNA methylation and one-carbon biomarkers in the Women's Health Initiative Observational Study cohort.

Bae S, Ulrich CM, Bailey LB, Malysheva O, Brown EC, Maneval DR, Neuhouser ML, Cheng TY, Miller JW, Zheng Y, Xiao L, Hou L, Song X, Buck K, Beresford SA, Caudill MA.

Epigenetics. 2014 Mar;9(3):396-403. doi: 10.4161/epi.27323. Epub 2013 Dec 3.

15.

Hypomethylation of serum blood clot DNA, but not plasma EDTA-blood cell pellet DNA, from vitamin B12-deficient subjects.

Quinlivan EP, Crider KS, Zhu JH, Maneval DR, Hao L, Li Z, Rasmussen SA, Berry RJ, Bailey LB.

PLoS One. 2013 Jun 13;8(6):e65241. doi: 10.1371/journal.pone.0065241. Print 2013.

16.

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF.

J Urol. 2013 Sep;190(3):850-6. doi: 10.1016/j.juro.2013.03.030. Epub 2013 Mar 15.

17.

B vitamin intakes and incidence of colorectal cancer: results from the Women's Health Initiative Observational Study cohort.

Zschäbitz S, Cheng TY, Neuhouser ML, Zheng Y, Ray RM, Miller JW, Song X, Maneval DR, Beresford SA, Lane D, Shikany JM, Ulrich CM.

Am J Clin Nutr. 2013 Feb;97(2):332-43. doi: 10.3945/ajcn.112.034736. Epub 2012 Dec 19.

18.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA.

Gut. 2013 Jan;62(1):112-20. doi: 10.1136/gutjnl-2012-302529. Epub 2012 Mar 30.

19.

Genomic DNA methylation changes in response to folic acid supplementation in a population-based intervention study among women of reproductive age.

Crider KS, Quinlivan EP, Berry RJ, Hao L, Li Z, Maneval D, Yang TP, Rasmussen SA, Yang Q, Zhu JH, Hu DJ, Bailey LB.

PLoS One. 2011;6(12):e28144. doi: 10.1371/journal.pone.0028144. Epub 2011 Dec 7.

20.

Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys.

Veneziale RW, Kishnani NS, Nelson J, Resendez JC, Frank DW, Cai XY, Xie L, Cullen C, Frugone CA, Rosenfeld C, Hubbell J, Maxwell SE, Sugarman BJ, Hutchins B, Maneval D, Treinen KA.

Gene Ther. 2012 Jul;19(7):742-51. doi: 10.1038/gt.2011.116. Epub 2011 Sep 8.

PMID:
21900961
21.

MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation.

Crider KS, Zhu JH, Hao L, Yang QH, Yang TP, Gindler J, Maneval DR, Quinlivan EP, Li Z, Bailey LB, Berry RJ.

Am J Clin Nutr. 2011 Jun;93(6):1365-72. doi: 10.3945/ajcn.110.004671. Epub 2011 Apr 20.

PMID:
21508090
22.

Simulation of a 6 MV Elekta Precise Linac photon beam using GATE/GEANT4.

Grevillot L, Frisson T, Maneval D, Zahra N, Badel JN, Sarrut D.

Phys Med Biol. 2011 Feb 21;56(4):903-18. doi: 10.1088/0031-9155/56/4/002. Epub 2011 Jan 20.

PMID:
21248389
23.

Daily intake of 4 to 7 microg dietary vitamin B-12 is associated with steady concentrations of vitamin B-12-related biomarkers in a healthy young population.

Bor MV, von Castel-Roberts KM, Kauwell GP, Stabler SP, Allen RH, Maneval DR, Bailey LB, Nexo E.

Am J Clin Nutr. 2010 Mar;91(3):571-7. doi: 10.3945/ajcn.2009.28082. Epub 2010 Jan 13.

PMID:
20071646
24.

Herceptin.

Shepard HM, Jin P, Slamon DJ, Pirot Z, Maneval DC.

Handb Exp Pharmacol. 2008;(181):183-219. Review.

PMID:
18071947
25.

Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer.

Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, Connor RJ.

Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):389-94. Epub 2007 Aug 9. Review.

PMID:
17692556
26.

SCH 412499: biodistribution and safety of an adenovirus containing P21(WAF-1/CIP-1) following subconjunctival injection in Cynomolgus monkeys.

Veneziale RW, Bral CM, Sinha DP, Watkins RW, Cartwright ME, Rosenblum IY, Treinen KA, Kishnani NS, Nelson J, Chen Z, Faha B, Maneval D, Munger RJ, Cai XY, Cullen C, Arezzo JC.

Cutan Ocul Toxicol. 2007;26(2):83-105.

PMID:
17612977
27.

Holo-transcobalamin is an indicator of vitamin B-12 absorption in healthy adults with adequate vitamin B-12 status.

von Castel-Roberts KM, Morkbak AL, Nexo E, Edgemon CA, Maneval DR, Shuster JJ, Valentine JF, Kauwell GP, Bailey LB.

Am J Clin Nutr. 2007 Apr;85(4):1057-61.

PMID:
17413105
28.

Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma.

Brin E, Atencio I, Helmich BK, Maneval D, Laface D.

Cancer Gene Ther. 2006 Jul;13(7):664-75. Epub 2006 Mar 3.

PMID:
16514422
29.

Recombinant adenovirus-p21 attenuates proliferative responses associated with excessive scarring.

Gu D, Atencio I, Kang DW, Looper LD, Ahmed CM, Levy A, Maneval D, Zepeda ML.

Wound Repair Regen. 2005 Sep-Oct;13(5):480-90.

PMID:
16176456
30.

Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.

Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R.

Cancer Gene Ther. 2006 Feb;13(2):169-81.

PMID:
16082381
31.

Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses.

Machemer T, Engler H, Tsai V, Lee S, Cannon-Carlson S, Voloch M, Schluep T, Ravindran S, Vellekamp G, Brin E, Cornell D, Sutjipto S, Wen SF, Horn M, Van Rooijen N, Maneval D, Hutchins B, LaFace D.

Mol Ther. 2005 Aug;12(2):254-63.

32.
33.

Transcobalamin 776C->G polymorphism negatively affects vitamin B-12 metabolism.

von Castel-Dunwoody KM, Kauwell GP, Shelnutt KP, Vaughn JD, Griffin ER, Maneval DR, Theriaque DW, Bailey LB.

Am J Clin Nutr. 2005 Jun;81(6):1436-41.

PMID:
15941899
34.

The methylenetetrahydrofolate reductase 677C->T polymorphism and dietary folate restriction affect plasma one-carbon metabolites and red blood cell folate concentrations and distribution in women.

Davis SR, Quinlivan EP, Shelnutt KP, Maneval DR, Ghandour H, Capdevila A, Coats BS, Wagner C, Selhub J, Bailey LB, Shuster JJ, Stacpoole PW, Gregory JF 3rd.

J Nutr. 2005 May;135(5):1040-4.

PMID:
15867278
35.

p21WAF-1/Cip-1 gene therapy as an adjunct to glaucoma filtration surgery.

Atencio IA, Chen Z, Nguyen QH, Faha B, Maneval DC.

Curr Opin Mol Ther. 2004 Dec;6(6):624-8. Review.

PMID:
15663327
36.

Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model.

Tsai V, Johnson DE, Rahman A, Wen SF, LaFace D, Philopena J, Nery J, Zepeda M, Maneval DC, Demers GW, Ralston R.

Clin Cancer Res. 2004 Nov 1;10(21):7199-206.

37.

Methionine synthase reductase 66A->G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C->T variant.

Vaughn JD, Bailey LB, Shelnutt KP, Dunwoody KM, Maneval DR, Davis SR, Quinlivan EP, Gregory JF 3rd, Theriaque DW, Kauwell GP.

J Nutr. 2004 Nov;134(11):2985-90.

PMID:
15514263
38.

Methylenetetrahydrofolate reductase 677C-->T polymorphism affects DNA methylation in response to controlled folate intake in young women.

Shelnutt KP, Kauwell GP, Gregory JF 3rd, Maneval DR, Quinlivan EP, Theriaque DW, Henderson GN, Bailey LB.

J Nutr Biochem. 2004 Sep;15(9):554-60.

PMID:
15350988
39.

Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.

Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ.

Mol Ther. 2004 Sep;10(3):525-32.

40.

Gene therapy using p21WAF-1/Cip-1 to modulate wound healing after glaucoma trabeculectomy surgery in a primate model of ocular hypertension.

Heatley G, Kiland J, Faha B, Seeman J, Schlamp CL, Dawson DG, Gleiser J, Maneval D, Kaufman PL, Nickells RW.

Gene Ther. 2004 Jun;11(12):949-55.

PMID:
14985792
41.

Folate status response to controlled folate intake is affected by the methylenetetrahydrofolate reductase 677C-->T polymorphism in young women.

Shelnutt KP, Kauwell GP, Chapman CM, Gregory JF 3rd, Maneval DR, Browdy AA, Theriaque DW, Bailey LB.

J Nutr. 2003 Dec;133(12):4107-11.

PMID:
14652356
42.

Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice.

Engler H, Machemer TR, Schluep T, Wen SF, Quijano E, Wills KN, Harper AE, Maneval DC, Conroy SE.

Mol Ther. 2003 Apr;7(4):558-64.

43.

Efficacy of adenoviral p53 delivery with SCH58500 in the intracranial 9l and RG2 models.

Bowers G, He J, Schulz K, Olivarria G, Maneval D, Olson JJ.

Front Biosci. 2003 May 1;8:a54-61.

PMID:
12700117
44.

Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.

Wen SF, Mahavni V, Quijano E, Shinoda J, Grace M, Musco-Hobkinson ML, Yang TY, Chen Y, Runnenbaum I, Horowitz J, Maneval D, Hutchins B, Buller R.

Cancer Gene Ther. 2003 Mar;10(3):224-38.

PMID:
12637944
45.

Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer.

Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF.

Cancer Gene Ther. 2002 Aug;9(8):687-91.

46.

Adenovirus-mediated gene therapy using human p21WAF-1/Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery.

Perkins TW, Faha B, Ni M, Kiland JA, Poulsen GL, Antelman D, Atencio I, Shinoda J, Sinha D, Brumback L, Maneval D, Kaufman PL, Nickells RW.

Arch Ophthalmol. 2002 Jul;120(7):941-9.

PMID:
12096965
47.

Vitamin B-12 status is inversely associated with plasma homocysteine in young women with C677T and/or A1298C methylenetetrahydrofolate reductase polymorphisms.

Bailey LB, Duhaney RL, Maneval DR, Kauwell GP, Quinlivan EP, Davis SR, Cuadras A, Hutson AD, Gregory JF 3rd.

J Nutr. 2002 Jul;132(7):1872-8.

PMID:
12097662
48.

Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles.

Demers GW, Sugarman BJ, Beltran JC, Westreich LN, Ahmed CM, Lau JY, Hong Z, Lanford RE, Maneval DC.

Toxicol Appl Pharmacol. 2002 Apr 1;180(1):36-42.

PMID:
11922775
49.

Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors.

Abe T, Wakimoto H, Bookstein R, Maneval DC, Chiocca EA, Basilion JP.

Cancer Gene Ther. 2002 Mar;9(3):228-35.

50.

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.

Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P, Quijano E, Engler H, Hutchins B, Maneval DC, Grace MJ, Fritz MA, Störkel S, Thüroff JW, Huber C, Schuler M.

J Clin Oncol. 2002 Feb 15;20(4):957-65.

PMID:
11844817

Supplemental Content

Loading ...
Support Center